SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA

Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti

– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals

– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at American Society of Hematology (ASH) Annual Meeting in December 2022 – – IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022 – – Cash runway into 2026 enables multiple clinical readouts across pipeline – – Cash and cash equivalents of $444.8 million as of September 30, 2022 – BOSTON and LONDON, Nov. 10, 2022 (GLOBE

- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today reported financial results

BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a

Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa's management team as Senior Vice President of Clinical Development, Innovative Medicines. "This is an exciting time for Centessa as we are focused on the next set of clinical milestones, including executing the pivotal program for our lead product candidate, SerpinPC for hemophilia, initiating the Phase 1/2a clinical studies for LB101, our first LockBody® candidate for solid tumors, and progressing MGX292 fo

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. "We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC program in Hemophilia B to move into registrational studies this year and continue to steadily advance our innovative rare disease and immuno-oncology pipeline," said Saurabh Saha, MD, PhD, Chief Executive Officer of Cente

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. In addition, the Company announced that Aaron Kantoff has resigned from the Company's Board, but will remain actively involved with the Company as an advisor. Both changes are effective July 1, 2022.  "I am very pleased to we

Scorpion Therapeutics, Inc. ("Scorpion Therapeutics"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors. Dr. Saha is currently the Chief Executive Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA) ("Centessa") and brings more than 20 years of biopharmaceutical research and development expertise to the role. "We are pleased to welcome Dr. Saha to our Board of Directors," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "His passion for discovering new cancer treatments, coupled with his track record o

Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating and announces Price Target of $14.

Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the price target from $8 to $11.

 Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.

BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 price target.

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 15.56 percent increase over losses of $(0.45) per share from the same period last year.

Shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) fell sharply during Friday’s session following third-quarter results. Take-Two reported third-quarter total net bookings of $1.34 billion, down 3% year-over-year. The company also revised its 2024 net bookings forecast to $5.25 billion and $5.3 billion, down from $5.45 billion and $5.55 billion earlier. Take-Two Interactive Software shares dipped 8.8% to $154.69 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Sunworks, Inc. (NASDAQ:SUNW) shares jumped 267% to $0.1990. Sunworks and three subsidiaries recently made the decision to cease operations and filed for Chapter 7 bankruptcy in the Uni